Skip to content

Osteoporosis drugs and repeated falls in postmenopausal women with diabetes

Repeated falls decreased in osteoporosis-drug groups and increased with standard care in an exploratory pilot analysis. The abstract does not quantify these changes.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

The number of women experiencing repeated falls decreased in each osteoporosis-drug group and increased with standard care. Questionnaire scores for fall risk also improved within the drug groups. These exploratory findings concern women with diabetes and high fracture risk; the abstract does not quantify the changes or show that fewer fractures occurred.

Keep in mind

This abstract-based analysis examined exploratory outcomes in a pilot trial. Missing absolute fall counts and score changes limit assessment of how practically important the findings were.

THE RESULT, WITH CONTEXT

What researchers found

Decrease in drug arms; increase with standard care

Participants experiencing repeated falls

After 72 weeks, the endpoint was more than one fall during the preceding 12 months; between-group p = 0.033. Absolute counts were not provided.

Osteoporos Int, 2025 · Original source ↓

Scores and falls measure different things

The Falls Risk Assessment Score is a questionnaire measure of fall risk. A lower score and fewer participants experiencing repeated falls are distinct findings; neither directly demonstrates that fractures were prevented.

The drugs were not ranked

Scores improved significantly from baseline within each drug group. The absence of significant improvement with standard care does not, by itself, establish a score difference between treatments or identify a superior drug.

CHECK THE ORIGINAL

The original publication

Anti-resorptive and anabolic therapies improve Falls Risk Assessment Score (FRAS) in postmenopausal women with type 2 diabetes mellitus.

Prasad TN, Flora SS, Bhadada SK et al.
Osteoporos Int · 2025

PubMed ID
40588549
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.